<DOC>
	<DOCNO>NCT00123253</DOCNO>
	<brief_summary>HIV lipodystrophy affect significant proportion patient treat combination antiretroviral therapy ( ART ) characterize excess visceral fat accumulation loss extremity subcutaneous fat , association dyslipidemia insulin resistance . Data previous randomize , placebo-controlled trial demonstrate daily administration 2mg TH9507 , growth hormone release factor ( GRF ) , HIV patient excess abdominal fat accumulation 12 week result decrease visceral adipose tissue ( VAT ) trunk fat , significant change limb fat subcutaneous adipose tissue ( SAT ) . This study aim assess efficacy safety 2 mg TH9507 large population HIV patient treat ART experience excess abdominal fat accumulation .</brief_summary>
	<brief_title>TH9507 Patients With HIV-Associated Lipodystrophy</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Growth Hormone-Releasing Hormone</mesh_term>
	<criteria>Ages 18 65 year inclusive HIV positive ; CD4 cell count &gt; 100 cells/mm3 ; viral load &lt; 10,000 copies/mL ( stable 8 week ) On stable ART regimen least 8 week prior randomization Have evidence abdominal fat accumulation define follow anthropometric cut value : For male : waist circumference &gt; 95 cm waist hip ratio &gt; 0.94 ; For female : waist circumference &gt; 94 cm waist hip ratio &gt; 0.88 . Females childbearing potential pregnant lactating ; normal mammography within 6 month study . Signed informed consent Body mass index &lt; 20 kg/m2 Opportunistic infection ; HIVrelated disease within 3 month study . History malignancy ; active neoplasm . Prostatespecific antigen ( PSA ) &gt; 5 ng/mL screen Hypopituitarism ; history pituitary tumor/surgery ; head irradiation ; head trauma affect somatotropic axis . Untreated hypothyroidism Type 1 diabetic type 2 diabetic oral hypoglycemic insulin sensitize agent within 6 month study ALT AST &gt; 3 x ULN ; serum creatinine &gt; 133 mmol/L ( 1.5 mg/dL ) ; hemoglobin 20 g/L LLN ; fast blood glucose &gt; 8.33 mmol/L ( 150 mg/dL ) ; fast triglyceride &gt; 11.3 mmol/L ( 0.99 g/dL ) . Untreated hypertension Change antihyperlipemic regimen within 3 month prior study Change testosterone regimen and/or supraphysiological dose testosterone Estrogen therapy Anoretics/anorexigenics antiobesity agent within 3 month study Growth hormone ( GH ) ; GH secretagogues ; growth hormone release factor ( GRF ) product ; IGF1 ; IGFBP3 within 6 month study . Drug alcohol dependence use methadone within 6 month study entry Participation clinical trial investigational drug/device within 30 day screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>Lipodystrophy</keyword>
	<keyword>Abdominal fat accumulation</keyword>
	<keyword>Growth hormone release factor/Growth hormone release hormone</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>